Characterizing Cardiotoxicity of FDA-Approved Soft Tissue Sarcoma Targeted Therapies and Immune Checkpoint Inhibitors: A Systematic Review is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0.241. It has been cited 4 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: P50-CA140158
NIH
Grant: K23-HL155890
NIH
Grant: R01HL168045
NIH
Grant: R01HL170038
NHLBI NIH HHS
Grant: K23 HL155890
NCI NIH HHS
Grant: P50 CA140158
American Heart Association
Grant: Robert Wood Johnson Foundation (Harold Amos) grant
FWCI
1.67
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords